Gufic Biosciences gains on Aussie, Brazilian nod to pain-killer drug

"The medicine will be used for short-term treatment of acute pain and post-operative pain in adult patients,” the company said in a regulatory filing at the exchanges.

September 12, 2023 / 12:05 IST

Gufic Biosciences is engaged in the business of manufacturing and distribution of pharmaceutical products, including formulations, active pharmaceutical ingredients, and herbal healthcare solutions.

26 Aug, 2025 12:21

Volume

Todays L/H

Gufic Biosciences shares traded 3 percent higher intraday on September 12 after drug regulators of Brazil and Australia gave the green light to its pain-killer drug.

“The company has received approval from the Therapeutic Group Administration (TGA), Australia and the National Health Surveillance Agency (ANVISA), Brazil, for Parecoxib Sodium 40 mg Lyophilized Powder for Injection. It will be used for short-term treatment of acute pain and post-operative pain in adult patients,” the company said in a regulatory filing at the exchanges.

At 11.45 am on the NSE, the Gufic Biosciences stock was quoting at Rs 305.35, up Rs 8.85, or 2.98 percent.

Follow our live blog for all the market action

In the April to June quarter, the company reported an 18.18 percent year-on-year (YoY) rise in its revenue from operations at Rs 195 crore. Its net profit for the quarter remained flat on a yearly basis at Rs 21 crore, while operating profit margins shrank 200 basis points to 18 percent.

Gufic Biosciences is engaged in the business of manufacturing and distribution of pharmaceutical products, including formulations, active pharmaceutical ingredients, and herbal healthcare solutions.